Markets | |
The world is becoming increasingly connected, and there’s no better proof of this than the hotel industry. Business travel and tourism fuel the global hotel industry, and there’s no sign of this growth slowing down. If you are interested in investing in the hotel industry, a review of ... Read the Full Story |
|
From Our Partners | | Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI breakthrough they call 'M.A.G.I.' will collide with a rare market pattern by July 30.
That pattern carries a 100% historical track record. The last time it triggered, early investors had a chance to turn $10,000 into as much as $350,000 in roughly 12 months. | | See the full breakdown of their AI prediction before July 30 |
|
Markets | |
If someone were to say that we live in a “post-unicorn era,” they probably wouldn't be too far off. Some have been projecting such an era as far back as 2016, and with the recent issues surrounding WeWork, it's easy to see that if the unicorn era weren't dead before, it probably is now... Read the Full Story |
|
Markets | | Shares of DocuSign (NASDAQ: DOCU) finished last week at all-time highs after smashing analyst estimates for their earnings and revenue in their Q3 report which was released after Thursday’s session. This comes after upward guidance from management at their last quarterly release in September a... Read the Full Story |
|
From Our Partners | | The Buffett Indicator once flagged the 1929, 1969, and 2000 market peaks - and it's now at 231%, its highest reading in history.
Gold analyst Garrett Goggin, CFA, CMT, has tracked this signal for years and says the pattern points to money rotating from overpriced tech into gold.
Porter Stansberry has called Goggin the most knowledgeable gold investor in the world. | | See Garrett Goggin's four top gold mining picks now |
|
Markets | | Scalping is a style of intraday trading that concentrates on taking high probability set-ups to profit off short-term price moves. Traders tend to use larger sized shares for smaller price gains. This style of trading requires high-probability strategies and disciplined execution. Over 70-percent of... Read the Full Story |
|
Markets | | Kroger’s (KR)management made two major missteps with the Restock Kroger plans. The first was their overaggressive plans to grow business in an attempt to compete with Walmart (WMT), Target (TGT), and Amazon (AMZN). The second was failing to realize the mistake soon enough. Now, with the compet... Read the Full Story |
|
From Our Partners | | A couple of years ago, we started playing with the massive amounts of data that MarketBeat takes in everyday trying to figure out if there was a way to identify short term trading wins. By analyzing earnings data, news sentiment, analyst recommendations, insider transactions and dozens of other data points, we think we’ve found an algorithm that finds interesting short-term stock ideas. We call that algorithm the IdeaEngine and its stock ideas are published on MarketBeat All Access every Monday morning. We make one IdeaEngine idea available free every Monday as an SMS alert. We’ll be releasing the next IdeaEngine alert on Monday morning, so make sure you are signed up before then. | | Get MarketBeat IdeaEngine Alerts (Free) |
|
Markets | | Salesforce.com (CRM) reported earnings this morning and shares are tumbling. The company reported a strong 33% topline growth for the 3rd quarter and provided robust guidance yet not quite good enough for investors. What we have is a classic case of unfulfilled expectations in an overexuberant marke... Read the Full Story |
|
Markets | |
Have you ever heard a trader talking about “reading the tape”? This is a term that advanced traders use to describe looking at Level II quotes. Level II quotes are great for traders because they allow us to get a little more information about the magnitude of the buying and selling of ... Read the Full Story |
|
Markets | | Shares of Veeva Systems (NYSE: VEEV) kept investors guessing after the company’s Q3 earnings last week. The stock whipped around a 12% range from Tuesday’s close on Wednesday following the release the previous evening. With markets shut on Thursday, they went into the Thanksgiving holida... Read the Full Story |
|
Healthcare | |
Pharmaceutical stocks are an important and interesting part of the healthcare market, and of the overall market as well. For investors who are interested in learning more about the pharmaceutical industry, a good place to start is with the following companies, which are some of the largest pharmac... Read the Full Story |
|
Markets | |
Money makes the world go around—at least in terms of driving a complex economy. Financial stocks are stocks issued by companies in the business of finance: banks, investment houses, credit unions, credit cards, and payment processing companies. These companies help individuals and organizati... Read the Full Story |
|
The Early Bird Stock Of The Day Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. | | View Today's Stock Pick |
|
